Are these the exact same investigators as for Rindo? Duke is pretty big and has many investigators. Even if these were the same investigators, Rindo is already very close to commercialization in the bag and they are allowed to mingle with other projects.
Marucci has consistently put the break on PPS by orchestraiting the offerings. He has ensured the future of CLDX very well with all the cash in the bank. A side effect is that shorts know that just about any good news is always followed by a stock offering, andmore if there are "investor presentations" in the schedule. Shorts (which might also be long term investors taking advantage a bit) have taken advantage of this predictability.
No press release on this new clinical trial yet. The preclinical data must be very compealing for Celldex to select a Pfizer drug and bear the full cost of this trial. Who knows, maybe Pfizer did join in and will share the costs.